Pranlukast
Chemical compound
- R03DC02 (WHO)
- N-[4-oxo-2-(1H-tetrazol-5-yl)-4H-chromen-8-yl]-4-(4-phenylbutoxy)benzamide
- 103177-37-3
Y
- 4887
- 3634
- DB01411 Y
- 4718 Y
- TB8Z891092
- ChEMBL21333 Y
- DTXSID3043782
- Interactive image
- O=C(Nc2cccc3c(=O)cc(c1nn[nH]n1)oc23)c5ccc(OCCCCc4ccccc4)cc5
InChI
- InChI=1S/C27H23N5O4/c33-23-17-24(26-29-31-32-30-26)36-25-21(23)10-6-11-22(25)28-27(34)19-12-14-20(15-13-19)35-16-5-4-9-18-7-2-1-3-8-18/h1-3,6-8,10-15,17H,4-5,9,16H2,(H,28,34)(H,29,30,31,32)Y
- Key:NBQKINXMPLXUET-UHFFFAOYSA-NY
Pranlukast (brand name Onon, オノン) is a cysteinyl leukotriene receptor-1 antagonist. This drug works similarly to Merck & Co.'s montelukast (Singulair). It is widely used in Japan.
Medications of this class, which go under a variety of names according to whether one looks at the American, British or European system of nomenclature, have as their primary function the antagonism of bronchospasm caused, principally in asthmatics, by an allergic reaction to accidentally or inadvertently encountered allergens.[2]
Medications of this group are normally used as an adjunct to the standard therapy of inhaled steroids with inhaled long- and/or short-acting beta-agonists. There are several similar medications in the group; all appear to be equally effective. Pranlukast is also reported as potential inhibitor of Mycobacterium tuberculosis infection in experimental models.[3]
References
- ^ a b Nakade S, Ueda S, Ohno T, Nakayama K, Miyata Y, Yukawa E, Higuchi S (April 2006). "Population pharmacokinetics of pranlukast hydrate dry syrup in children with allergic rhinitis and bronchial asthma". Drug Metabolism and Pharmacokinetics. 21 (2): 133–139. doi:10.2133/dmpk.21.133. PMID 16702733. Archived from the original on 2008-09-17.
- ^ Singh RK, Tandon R, Dastidar SG, Ray A (November 2013). "A review on leukotrienes and their receptors with reference to asthma". The Journal of Asthma. 50 (9): 922–931. doi:10.3109/02770903.2013.823447. PMID 23859232. S2CID 11433313.
- ^ Mishra A, Mamidi AS, Rajmani RS, Ray A, Roy R, Surolia A (April 2018). "An allosteric inhibitor of Mycobacterium tuberculosis ArgJ: Implications to a novel combinatorial therapy". EMBO Molecular Medicine. 10 (4): e8038. doi:10.15252/emmm.201708038. PMC 5887547. PMID 29483133.
- v
- t
- e
| Short-acting β2 agonists | |
|---|---|
| Long-acting β2 agonists |
|
| Ultra-long-acting β2 agonists | |
| Other |
muscarinic antagonist
| Leukotriene antagonists |
|
|---|---|
| Arachidonate 5-lipoxygenase inhibitors | |
| Thromboxane receptor antagonists | |
| Non-xanthine PDE4 inhibitors |
- Aclidinium bromide/formoterol
- Beclometasone/formoterol
- Beclometasone/formoterol/glycopyrronium bromide
- Budesonide/formoterol
- Budesonide/glycopyrronium bromide/formoterol
- Fluticasone furoate/umeclidinium bromide/vilanterol
- Fluticasone furoate/vilanterol
- Fluticasone propionate/salmeterol
- Glycopyrronium bromide/formoterol
- Indacaterol/glycopyrronium bromide
- Indacaterol/glycopyrronium bromide/mometasone
- Indacaterol/mometasone
- Ipratropium bromide/salbutamol
- Mometasone/formoterol
- Salbutamol (albuterol)/budesonide
- Umeclidinium bromide/vilanterol
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
